晚期透明细胞肾细胞癌中免疫检查点抑制剂的当代综述
A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma.
作者信息
Yu Eun-Mi, Linville Laura, Rosenthal Matthew, Aragon-Ching Jeanny B
机构信息
GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA.
Department of Internal Medicine, George Washington University Medical Center, Washington, DC 20037, USA.
出版信息
Vaccines (Basel). 2021 Aug 18;9(8):919. doi: 10.3390/vaccines9080919.
Abstract
The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and survival, combination therapies with immune checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors have further improved outcomes. This article reviews the landmark trials that have led to the approval of IO therapies, including the Checkmate 214 trial and combination IO/VEGF TKI therapies with Checkmate 9ER, CLEAR, and Keynote-426, and it includes a discussion on promising therapies moving in the future.
摘要
在过去几年中，检查点抑制剂在晚期和转移性肾细胞癌（RCC）中的应用迅速发展。虽然免疫肿瘤学（IO）药物治疗已成功改善了反应率和生存率，但免疫检查点抑制剂与血管内皮生长因子（VEGF）抑制剂的联合治疗进一步改善了治疗效果。本文回顾了促成IO疗法获批的里程碑式试验，包括Checkmate 214试验以及Checkmate 9ER、CLEAR和Keynote-426等IO/VEGF酪氨酸激酶抑制剂联合疗法，并讨论了未来有前景的治疗方法。
相似文献
1
A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma.晚期透明细胞肾细胞癌中免疫检查点抑制剂的当代综述
Vaccines (Basel). 2021 Aug 18;9(8):919. doi: 10.3390/vaccines9080919.
2
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time.IO-IO 与 IO-TKI 在转移性肾细胞癌患者中的疗效比较：一项随时间推移的结构化系统评价。
Semin Oncol. 2022 Oct;49(5):394-399. doi: 10.1053/j.seminoncol.2022.10.001. Epub 2022 Oct 23.
3
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.2018 年转移性透明细胞肾细胞癌的系统治疗：当前范例、免疫治疗的应用及未来方向。
Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13.
4
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：纳武利尤单抗联合卡博替尼加入免疫检查点抑制联合治疗用于治疗初治转移性透明细胞肾细胞癌。
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
5
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.免疫肿瘤和 VEGF 靶向治疗联合治疗后晚期透明细胞肾细胞癌的系统治疗。
BMC Urol. 2020 Jul 2;20(1):84. doi: 10.1186/s12894-020-00647-w.
6
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.2021 年更新版欧洲泌尿外科学会肾癌指南：免疫检查点抑制剂联合治疗用于治疗初治转移性透明细胞肾细胞癌，是标准治疗方案。
Eur Urol. 2021 Oct;80(4):393-397. doi: 10.1016/j.eururo.2021.04.042. Epub 2021 May 29.
7
Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.评估导致一线免疫检查点阻断联合治疗晚期肾细胞癌患者获批的临床试验中患者报告结局（PROs）方案内容和报告情况——患者的呼声还是错失的机会。
Clin Genitourin Cancer. 2022 Apr;20(2):e158-e165. doi: 10.1016/j.clgc.2021.12.002. Epub 2021 Dec 10.
8
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?免疫肿瘤联合治疗中晚期或中高危国际转移性肾细胞癌数据库联盟标准治疗的晚期肾细胞癌患者的真实世界结局：风险组的疗效差异？
Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.
9
Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.重塑晚期肾细胞癌患者的治疗模式和改善患者管理：肾细胞癌患者的最佳管理。
Curr Treat Options Oncol. 2022 Apr;23(4):609-629. doi: 10.1007/s11864-022-00966-0. Epub 2022 Mar 22.
10
Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.转移性肾细胞癌中对 VEGFR-TKI 和免疫检查点抑制剂耐药的决定因素。
J Exp Clin Cancer Res. 2021 Jun 7;40(1):186. doi: 10.1186/s13046-021-01961-3.
引用本文的文献
1
Overexpression of mG writers METTL1 and BUD23 confers oncogenicity in kidney renal clear cell carcinoma.甲基化修饰蛋白METTL1和BUD23的过表达赋予肾透明细胞癌致癌性。
J Pathol. 2025 Sep;267(1):1-9. doi: 10.1002/path.6453. Epub 2025 Jul 18.
2
Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance.一种免疫检查点抑制剂治疗耐药的自发性小鼠肾透明细胞癌模型的表征
Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.
3
Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report.免疫检查点抑制剂治疗后转移性肾细胞癌患者出现的超进展性疾病：一例报告
Cureus. 2022 Oct 11;14(10):e30194. doi: 10.7759/cureus.30194. eCollection 2022 Oct.
4
The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis.肾细胞癌患者原发性病灶肿瘤免疫微环境与转移时间的相关性：一项回顾性分析
Cancers (Basel). 2022 Oct 26;14(21):5258. doi: 10.3390/cancers14215258.
5
Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.铜死亡状态影响肾透明细胞癌患者免疫治疗和靶向治疗的治疗选择。
Front Immunol. 2022 Aug 19;13:954440. doi: 10.3389/fimmu.2022.954440. eCollection 2022.
6
Decoding the Immune Microenvironment of Clear Cell Renal Cell Carcinoma by Single-Cell Profiling to Aid Immunotherapy.通过单细胞分析解析透明细胞肾细胞癌的免疫微环境以辅助免疫治疗。
Front Immunol. 2022 Jun 24;13:791158. doi: 10.3389/fimmu.2022.791158. eCollection 2022.
7
Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.免疫检查点抑制剂时代的转移性透明细胞肾细胞癌：治疗方法与正在进行的试验
Cancers (Basel). 2022 Jun 10;14(12):2867. doi: 10.3390/cancers14122867.
8
Alcohol and Head and Neck Cancer: Updates on the Role of Oxidative Stress, Genetic, Epigenetics, Oral Microbiota, Antioxidants, and Alkylating Agents.酒精与头颈癌：氧化应激、遗传、表观遗传学、口腔微生物群、抗氧化剂及烷化剂作用的最新进展
Antioxidants (Basel). 2022 Jan 11;11(1):145. doi: 10.3390/antiox11010145.
9
Prognostic Value of Long Noncoding RNA DLEU2 and Its Relationship with Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.长链非编码RNA DLEU2在肾透明细胞癌和肝细胞癌中的预后价值及其与免疫浸润的关系
Int J Gen Med. 2021 Nov 11;14:8047-8064. doi: 10.2147/IJGM.S336428. eCollection 2021.
本文引用的文献
1
Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.尼伏鲁单抗在晚期移行细胞癌中的个体化免疫治疗方法。
J Clin Oncol. 2022 Jul 1;40(19):2128-2137. doi: 10.1200/JCO.21.02631. Epub 2022 Mar 11.
2
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
3
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
4
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
5
Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer.代谢组学评估非小细胞肺癌患者对免疫检查点抑制剂的反应
Cancers (Basel). 2020 Nov 30;12(12):3574. doi: 10.3390/cancers12123574.
6
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.挽救性依匹单抗和纳武利尤单抗治疗既往免疫检查点抑制剂治疗后转移性肾细胞癌患者。
J Clin Oncol. 2020 Sep 20;38(27):3088-3094. doi: 10.1200/JCO.19.03315. Epub 2020 Jun 3.
7
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.评估免疫治疗再挑战治疗肾细胞癌患者的安全性和疗效。
JAMA Oncol. 2020 Oct 1;6(10):1606-1610. doi: 10.1001/jamaoncol.2020.2169.
8
Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.Rocapuldencel-T 联合舒尼替尼作为转移性肾细胞癌一线治疗的 ADAPT 阶段 3 研究结果。
Clin Cancer Res. 2020 May 15;26(10):2327-2336. doi: 10.1158/1078-0432.CCR-19-2427. Epub 2020 Feb 7.
9
Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.透明细胞肾细胞癌中的肿瘤微环境动态。
Cancer Discov. 2019 Oct;9(10):1349-1357. doi: 10.1158/2159-8290.CD-19-0499. Epub 2019 Sep 16.
10
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
Zotero 插件